Melanoma Treatment in Cuba: Skin Cancer Oncology Care

Melanoma Treatment in Cuba

Cuba provides comprehensive melanoma treatment through its national oncology network, offering surgical excision, lymph node evaluation, immunotherapy, targeted therapy, and chemotherapy for advanced disease. Cuban oncology centers follow international treatment guidelines and treat both local and international patients with multidisciplinary care.

Melanoma is the most serious type of skin cancer, accounting for the majority of skin cancer deaths despite being less common than basal cell and squamous cell carcinomas. Incidence has been rising globally, largely due to ultraviolet (UV) radiation exposure. Cuba, with its tropical climate and predominantly outdoor lifestyle for much of the population, has significant experience in melanoma management.

The country's biotechnology sector, led by the Center of Molecular Immunology (CIM), also conducts research into immunotherapeutic approaches relevant to melanoma. Immunotherapy has become a cornerstone of advanced melanoma treatment worldwide, and Cuba's expertise in cancer immunology positions it within this evolving field.

Conventional Treatment Options

Cuba's melanoma treatment follows standard international protocols:

• Surgical excision — Wide local excision of the primary melanoma with appropriate margins based on Breslow thickness. This is the primary treatment for localized melanoma. • Sentinel lymph node biopsy — For melanomas thicker than 0.8mm or with ulceration, to determine if cancer has spread to nearby lymph nodes. • Lymph node dissection — If sentinel nodes are positive, complete lymph node dissection may be performed. • Immunotherapy — For advanced melanoma (stage III unresectable or stage IV), immunotherapy is the standard of care. This may include checkpoint inhibitors (anti-PD-1, anti-CTLA-4) where available. • Targeted therapy — For melanomas with BRAF V600 mutations, BRAF and MEK inhibitor combinations. BRAF mutation testing is essential for treatment planning. • Chemotherapy — Less commonly used now that immunotherapy and targeted therapy are available, but may be used in selected cases. • Radiation therapy — For specific indications including brain metastases, symptomatic bone metastases, or as adjuvant therapy in selected cases. • Palliative care — For advanced disease, focusing on quality of life.

Treatment plans are individualized based on melanoma stage, Breslow thickness, ulceration status, BRAF mutation status, and the patient's overall health.

Cuban Biotechnology & Immunotherapy

Cuba's Center of Molecular Immunology (CIM) has expertise relevant to melanoma immunotherapy:

• Cancer immunology research — Cuba's immunology research infrastructure, which produced CIMAvax-EGF and CIMAher, is positioned to contribute to melanoma immunotherapy research. Melanoma is one of the most immunogenic cancers, meaning the immune system can sometimes recognize and attack melanoma cells, making it particularly responsive to immunotherapy approaches.

• CIMAher (nimotuzumab) — While CIMAher targets EGFR (not the primary target in melanoma), research into multi-target immunotherapy approaches may include melanoma. EGFR is expressed in some melanomas, though it is not the primary driver.

• CIMAvax-EGF — The EGF-targeting vaccine approach has been studied primarily in lung cancer, but the platform technology could potentially be adapted for other cancers. Research into its applicability to melanoma is theoretical at this stage.

• Immunotherapy landscape — Globally, melanoma treatment has been transformed by checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) and oncolytic virus therapy (T-VEC). Cuba's research into cancer immunology positions it within this evolving field, though access to specific checkpoint inhibitors may vary.

It is important to note that Cuba's specific immunotherapy products (CIMAvax, CIMAher) are not standard treatments for melanoma. Conventional treatment (surgery, approved immunotherapy, targeted therapy) remains the standard of care. Experimental approaches may be available in research contexts.

International Patient Journey

For international patients seeking melanoma treatment in Cuba, SMC Salud coordinates:

• Medical review — Submission and review of pathology reports (including Breslow thickness, ulceration status, mitotic rate), sentinel lymph node biopsy results, BRAF mutation testing, staging imaging, and prior treatment records. • Treatment proposal — Individualized treatment plan with transparent cost breakdown. • Travel coordination — Medical visa, flights, accommodation, airport reception. • Treatment at Havana's oncology facilities — Multidisciplinary care including surgical oncology, medical oncology, and radiation oncology. • Interpreter services — Professional medical interpreters. • Comprehensive medical report — For the home-country oncologist/dermatologist. • Telemedicine follow-up — Continued consultation and surveillance planning.

The multidisciplinary team includes dermatologists, surgical oncologists, medical oncologists, radiation oncologists, pathologists, and radiologists, ensuring comprehensive evaluation and treatment planning.